Advertisement
Singapore markets close in 3 hours 40 minutes
  • Straits Times Index

    3,286.73
    -1.02 (-0.03%)
     
  • Nikkei

    38,042.93
    +414.45 (+1.10%)
     
  • Hang Seng

    17,608.27
    +323.73 (+1.87%)
     
  • FTSE 100

    8,078.86
    +38.48 (+0.48%)
     
  • Bitcoin USD

    64,224.48
    +59.53 (+0.09%)
     
  • CMC Crypto 200

    1,384.36
    +1.79 (+0.13%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • Dow

    38,085.80
    -375.12 (-0.98%)
     
  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     
  • Gold

    2,347.30
    +4.80 (+0.20%)
     
  • Crude Oil

    83.88
    +0.31 (+0.37%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • FTSE Bursa Malaysia

    1,573.86
    +4.61 (+0.29%)
     
  • Jakarta Composite Index

    7,115.99
    -39.31 (-0.55%)
     
  • PSE Index

    6,571.10
    -3.78 (-0.06%)
     

MEDNAX's (MD) Earnings Miss Estimates in Q1, Tumble Y/Y

MEDNAX, Inc. MD reported first-quarter 2020 adjusted earnings of 32 cents per share, missing the Zacks Consensus Estimate by 23.8%. Moreover, the bottom line plunged 50.8% year over year.

The company’s results were negatively impacted by the COVID-19 pandemic. In fact, the coronavirus outbreak dented patient volumes as well as revenue.

MEDNAX Inc Price and EPS Surprise

MEDNAX Inc Price and EPS Surprise
MEDNAX Inc Price and EPS Surprise

MEDNAX Inc price-eps-surprise | MEDNAX Inc Quote

Quarterly Details

The company generated revenues of $846 million, which missed the Zacks Consensus Estimate by 0.6%. Also, the top line slid 0.6% from the year-ago period.

Same unit revenues dipped 1% year over year.

General and administrative expenses inched 3.3% to $105.2 million due to higher general and administrative expenses.

Interest expense of the company declined 10.1% to $27.6 million on the back of lower borrowings.

In the quarter under review, EBITDA totaled $63.4 million, down 39.6% year over year.

The company invested $13.7 million in capital expenditures.

Withdrawal of Preliminary Outlook

Given the current pandemic-led uncertainty, the company scrapped its previously-announced quarterly and 2020 outlook.

Financial Update

As of Mar 31, 2020, the company had cash and cash equivalents of $312 million, up 177% from the level at 2019 end.

The company’s total debt of $2.1 billion was up 21.5% from the level at 2019 end while total assets worth $4.3 billion rose 4.2% from the level at 2019 end.

Cash flow used in operating activities was $146.4 million in the quarter under review, jumping 142.4% year over year.

Zacks Rank

MEDNAX currently carries a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Performance of Other Players

Of the other players from the same space that reported first-quarter results so far, Tenet Healthcare Corporation’s THC bottom line beat the Zacks Consensus Estimate while that of HCA Healthcare Inc HCA and Universal Health Services Inc UHS missed the mark.

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.

See 8 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Universal Health Services Inc (UHS) : Free Stock Analysis Report
 
Tenet Healthcare Corporation (THC) : Free Stock Analysis Report
 
HCA Healthcare Inc (HCA) : Free Stock Analysis Report
 
MEDNAX Inc (MD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research